About UCB SA
Ticker
info
UCB
Trading on
info
BR
ISIN
info
BE0003739530
Industry
info
Biotechnology
Sector
info
Healthcare
CEO
info
Dr. Jean-Christophe Tellier
Headquarters
info
Allée de la Recherche, 60, Brussels, undefined, Belgium, 1070
Employees
info
9,052
Website
info
ucb.com
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF-mediated diseases, as well as ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. In addition, the company offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx to treat plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; Fintepla for the treatment of Dravet/Lennox-Gastaut syndrome; and RYSTIGGO and ZILBRYSQ to treat people living with generalized myasthenia gravis. Further, it develops doxecitine/doxribtimine for TK2 deficiency disorder; fenfluramine to treat CDKL5 deficiency disorder; dapirolizumab pegol for systemic lupus erythematosus; STACCATO alprazolam for treating stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; UCB0222 for the treatment of Parkinson's disease; and UCB9741 and UCB1381 for atopic dermatitis. Additionally, it engages in the contract manufacturing activities. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Metrics
BasicAdvanced
Market cap
info
€35.2B
P/E ratio
info
27.8
EPS
info
€6.65
Dividend Yield
info
0.00%
Beta
info
0.27
Forward P/E ratio
info
25.32
EBIDTA
info
€1.49B
Ex dividend date
info
2025-04-25
Price & volume
Market cap
info
€35.2B
Average daily volume
info
0.2M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
€0.00
Dividend yield
info
0.00%
Forward dividend per share
info
€1.39
Forward dividend yield
info
0.73%
Payout ratio
info
21.96%
Valuation
P/E ratio
info
27.8
Forward P/E
info
25.32
PEG ratio
info
3.21
Trailing P/E
info
27.8
Price to sales
info
5.73
Price to book
info
3.74
Earnings
EPS
info
€6.65
EPS estimate (current quarter)
info
€0.00
EPS estimate (next quarter)
info
€0.00
EBITDA
info
€1.49B
Revenues (TTM)
info
€6.15B
Revenues per share (TTM)
info
€32.38
Technicals
Beta
info
0.27
52-week High
info
€206.50
52-week Low
info
€128.50
50-day moving average
info
€167.85
200-day moving average
info
€173.42
Short ratio
info
0
Short %
info
0.00%
Management effectiveness
ROE (TTM)
info
11.21%
ROA (TTM)
info
3.22%
Profit margin
info
17.31%
Gross profit margin
info
€4.4B
Operating margin
info
15.53%
Growth
Quarterly earnings growth (YoY)
info
2,612.10%
Quarterly revenue growth (YoY)
info
26.20%
Share stats
Outstanding Shares
info
190M
Float
info
120M
Insiders %
info
36.25%
Institutions %
info
39.00%
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
-
-
-
Q1 • 24Beat
-
-
-
Q2 • 24Beat
-
-
-
Q3 • 24Beat
€4.43
-
-
Q4 • 24Beat
-
-
-
Q1 • 25Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
€2.79B
€208M
7.45%
Q2 • 24
€3.36B
€857M
25.50%
Q4 • 24
20.42%
312.02%
242.14%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
€15.6B
€6.68B
42.72%
Q2 • 24
€17.3B
€7.32B
42.19%
Q4 • 24
10.99%
9.62%
-1.24%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
€377M
-
€-635M
€261M
Q2 • 24
€826M
-
€-144M
€708M
Q4 • 24
119.10%
-
-77.32%
171.26%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a UCB SA share?
Collapse

UCB SA shares are currently traded for undefined per share.

How many shares does UCB SA have?
Collapse

UCB SA currently has 190M shares.

Does UCB SA pay dividends?
Collapse

No, UCB SA doesn't pay dividends.

What is UCB SA 52 week high?
Collapse

UCB SA 52 week high is €206.50.

What is UCB SA 52 week low?
Collapse

UCB SA 52 week low is €128.50.

What is the 200-day moving average of UCB SA?
Collapse

UCB SA 200-day moving average is €173.42.

Who is UCB SA CEO?
Collapse

The CEO of UCB SA is Dr. Jean-Christophe Tellier.

How many employees UCB SA has?
Collapse

UCB SA has 9,052 employees.

What is the market cap of UCB SA?
Collapse

The market cap of UCB SA is €35.2B.

What is the P/E of UCB SA?
Collapse

The current P/E of UCB SA is 27.8.

What is the EPS of UCB SA?
Collapse

The EPS of UCB SA is €6.65.

What is the PEG Ratio of UCB SA?
Collapse

The PEG Ratio of UCB SA is 3.21.